Status message

Active context: kki_bg_colors_yellow

An Open-Label Extension Study of the Long-Term Safety, Tolerability and Efficacy of Drisapersen in US And Canadian Subjects with Duchenne Muscular Dystrophy

This is a phase III, multicenter, open-label, uncontrolled extension study in male subjects with DMD open to eligible US who previously participated in a GSK drisapersen study.

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.

Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.